Modifiers of Tumor Susceptibility in Murine Neuroblastoma

小鼠神经母细胞瘤肿瘤易感性的调节因素

基本信息

项目摘要

DESCRIPTION (provided by applicant): Neuroblastoma, a tumor of peripheral neural crest origin, is a common and lethal tumor of childhood. Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease. We generated a transgenic mouse model for high-risk neuroblastoma by directing expression of a MYCN transgene to the peripheral neural crest, under control of the Tyrosine Hydroxylase (TH) promoter. Genetic analyses identified conserved genetic changes between human and murine tumors, and argue that mice transgenic for TH-MYCN represent an important genetic model for childhood neuroblastoma. We hypothesize that the additional genetic and epigenetic lesions which contribute to neuroblastoma formation in the mouse will be in genes relevant to neuroblastoma in children. The long term objective of this application is to identify genetic and epigenetic changes in murine and human neuroblastoma. Genes identified in this study may reveal novel mechanisms and pathways relevant to human MYCN-amplified neuroblastoma, ultimately leading to novel therapeutic targets. Strains of mice differ in susceptibility to tumors. Mice transgenic for TH-MYCN in strain FVB/N do not develop tumors, nearly all transgenic mice in strain 129/SvJ die of tumors by 4 months of age, and 129/SvJ FVB/N F1 mice show 4% penetrance. These observations suggest that structural or epigenetic changes in germ line modifier genes differ between strains, interact with Mycn, and underlie the differences in susceptibility between strains. These strain-specific differences provide a critical resource to identify secondary genetic and epigenetic events important in both murine and human neuroblastoma. We propose to mobilize a powerful insertional mutagen, the vertebrate Sleeping Beauty (SB) transposon, and to combine use of somatic insertional mutagenesis with comparative genomic hybridization and modifier genetics to identify genes that influence susceptibility to tumors in murine neuroblastoma. Aim 1 uses SB transposon-based insertional mutagenesis to accelerate oncogenic mutations and to increase penetrance of tumors in F1 mice. Aim 2 applies array-based comparative genomic hybridization to characterize copy-number abnormalities in both spontaneous and transposon-induced tumors in F1 mice, to characterize strain-specific methylation patterns, and to identify epigenetic changes in tumors. Aim 3 validates and characterizes candidate genes in-vitro and in-vivo, prioritizing based on the involvement of specific candidate genes in human neuroblastoma.Narrative: Neuroblastoma is a common and frequently lethal tumor of children, for which current therapies are often ineffective. The long term objective of this application is to use a mouse model for neuroblastoma developed in our laboratory to identify genes important to the development of tumors in mice and in children with this disease. Genes identified in this study are likely to reveal novel mechanisms and pathways relevant to human neuroblastoma, ultimately leading to novel therapeutic targets.
描述(由申请人提供):神经母细胞瘤,一种外周神经rest起源的肿瘤,是一种常见且致命的儿童肿瘤。转录因子MYCN的扩增经常发生在该肿瘤中,与晚期疾病有关。我们通过控制酪氨酸羟化酶(Th)启动子的控制,通过将MYCN转基因的表达引向外周神经rest来生成高危神经母细胞瘤的转基因小鼠模型。遗传分析确定了人类和鼠肿瘤之间的保守遗传变化,并认为Th-Mycn的小鼠转基因代表了儿童神经母细胞瘤的重要遗传模型。我们假设有助于小鼠中神经母细胞瘤形成的其他遗传和表观遗传病变将与儿童的神经母细胞瘤相关。该应用的长期目标是确定鼠和人类神经母细胞瘤的遗传和表观遗传变化。这项研究中鉴定出的基因可能揭示了与人MyCN扩增的神经母细胞瘤相关的新型机制和途径,最终导致了新的治疗靶标。 小鼠的菌株在对肿瘤的敏感性方面有所不同。 FVB/N菌株中Th-Mycn的小鼠不发展肿瘤,到4个月大的肿瘤中,几乎所有转基因小鼠死于肿瘤,而129/SVJ FVB/N F1小鼠均显示出4%的渗透率。这些观察结果表明,菌株,与MYCN相互作用的生殖系修饰基因的结构或表观遗传变化不同,并构成了菌株之间易感性的差异。这些特异性差异提供了关键的资源,以识别在鼠和人类神经母细胞瘤中都很重要的二级遗传和表观遗传事件。 我们建议动员强大的插入诱变,脊椎动物睡美(SB)转座子,并将体细胞插入诱变与比较基因组杂交和修饰遗传学相结合,以识别影响鼠神经细胞瘤中肿瘤易感性的基因。 AIM 1使用基于SB转座子的插入诱变来加速致癌突变并增加F1小鼠肿瘤的渗透率。 AIM 2应用基于阵列的比较基因组杂交来表征F1小鼠中自发性和转座子诱导的肿瘤的拷贝数异常,以表征菌株特异性的甲基化模式,并鉴定肿瘤的表观遗传变化。 AIM 3验证并表征了候选基因在体外和体内,根据特定候选基因参与人类神经母细胞瘤的优先级。神经母细胞瘤是一种常见且经常致命的儿童肿瘤,当前治疗当前疗法通常是无效的。该应用的长期目的是将小鼠模型用于我们实验室中开发的神经母细胞瘤,以鉴定对小鼠和患有这种疾病儿童发育重要的基因。这项研究中鉴定出的基因可能揭示了与人类神经细胞瘤相关的新型机制和途径,最终导致了新的治疗靶标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM A WEISS其他文献

WILLIAM A WEISS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM A WEISS', 18)}}的其他基金

Integrating mass cytometric and transcriptomic profiles of solid tumors
整合实体瘤的质谱流式细胞术和转录组学特征
  • 批准号:
    8842954
  • 财政年份:
    2014
  • 资助金额:
    $ 33.73万
  • 项目类别:
Integrating mass cytometric and transcriptomic profiles of solid tumors
整合实体瘤的质谱流式细胞术和转录组学特征
  • 批准号:
    9060270
  • 财政年份:
    2014
  • 资助金额:
    $ 33.73万
  • 项目类别:
Integrating mass cytometric and transcriptomic profiles of solid tumors
整合实体瘤的质谱流式细胞术和转录组学特征
  • 批准号:
    8664234
  • 财政年份:
    2014
  • 资助金额:
    $ 33.73万
  • 项目类别:
Genetic network analysis of cancer targets
癌症靶点的遗传网络分析
  • 批准号:
    8495650
  • 财政年份:
    2013
  • 资助金额:
    $ 33.73万
  • 项目类别:
Genetic network analysis of cancer targets
癌症靶点的遗传网络分析
  • 批准号:
    9063479
  • 财政年份:
    2013
  • 资助金额:
    $ 33.73万
  • 项目类别:
Genetic network analysis of cancer targets
癌症靶点的遗传网络分析
  • 批准号:
    8843813
  • 财政年份:
    2013
  • 资助金额:
    $ 33.73万
  • 项目类别:
Regulation and function of the vascular niche in glioma recurrance
神经胶质瘤复发中血管生态位的调节和功能
  • 批准号:
    8741084
  • 财政年份:
    2011
  • 资助金额:
    $ 33.73万
  • 项目类别:
TARGETING MYCN PROTEIN WITH SMALL MOLECULES
用小分子靶向 MYCN 蛋白
  • 批准号:
    7897366
  • 财政年份:
    2010
  • 资助金额:
    $ 33.73万
  • 项目类别:
Mycn and Medulloblastoma
Mycn 和髓母细胞瘤
  • 批准号:
    8010619
  • 财政年份:
    2009
  • 资助金额:
    $ 33.73万
  • 项目类别:
Mycn and Medulloblastoma
Mycn 和髓母细胞瘤
  • 批准号:
    8410037
  • 财政年份:
    2009
  • 资助金额:
    $ 33.73万
  • 项目类别:

相似海外基金

NF2-associated meningiomas: From omics discovery to targeted therapy
NF2 相关脑膜瘤:从组学发现到靶向治疗
  • 批准号:
    10408180
  • 财政年份:
    2020
  • 资助金额:
    $ 33.73万
  • 项目类别:
NF2-Associated Meningiomas: From Omics Discovery to Targeted Therapy
NF2 相关脑膜瘤:从组学发现到靶向治疗
  • 批准号:
    10640996
  • 财政年份:
    2020
  • 资助金额:
    $ 33.73万
  • 项目类别:
NF2-associated meningiomas: From omics discovery to targeted therapy
NF2 相关脑膜瘤:从组学发现到靶向治疗
  • 批准号:
    10249966
  • 财政年份:
    2020
  • 资助金额:
    $ 33.73万
  • 项目类别:
Targeting cell cycle dysregulation in GIST
针对 GIST 细胞周期失调
  • 批准号:
    10443573
  • 财政年份:
    2019
  • 资助金额:
    $ 33.73万
  • 项目类别:
Targeting cell cycle dysregulation in GIST
针对 GIST 细胞周期失调
  • 批准号:
    9805478
  • 财政年份:
    2019
  • 资助金额:
    $ 33.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了